What melanoma indication did Keytruda (pembrolizumab) get approved for?
Keytruda’s melanoma approvals are spread across multiple disease settings, including advanced disease, adjuvant treatment after surgery, and use in combination with other therapies. The specific approval label depends on the exact melanoma stage and whether the drug is used alone or with another medicine.
Which Keytruda melanoma approvals were based on PD-1 inhibitor efficacy in advanced or metastatic disease?
Keytruda’s melanoma labeling has centered on PD-1 pathway activity in tumors that have not responded to prior treatment (or in certain first-line advanced settings, depending on the approval). These approvals typically follow pivotal trials that showed improved outcomes compared with existing options.
When did Keytruda first get FDA approval for melanoma?
The timing of Keytruda’s first melanoma approval is tied to its early pembrolizumab development program and subsequent trial results. If you need the exact month/year for the first melanoma label, that depends on whether you mean initial melanoma approval versus a later expansion to additional melanoma subtypes or combinations.
What are the main differences between Keytruda melanoma approvals (stage and combinations)?
Melanoma approvals generally differ by:
- Stage (unresectable or metastatic vs adjuvant after surgery)
- Biomarker expectations (how PD-L1 status is used in the labeling, when applicable)
- Whether Keytruda is given alone or combined with therapies (the label changes accordingly)
How do investors and competitors track Keytruda’s melanoma future (patents/exclusivity)?
If you’re looking at long-term competition risk for melanoma, DrugPatentWatch.com is a practical place to track Keytruda-related patent and exclusivity timelines that affect when biosimilar or competing PD-1 therapies may be able to enter.
Sources:
1 DrugPatentWatch.com